[
  {
    "ts": null,
    "headline": "3 Potential Mid-Cap Biotech Buyout Targets In 2026",
    "summary": "Read about the 3 potential midcap biotech stocks primed for acquisition in 2026 amid rising M&A activity.",
    "url": "https://finnhub.io/api/news?id=b80d4fcf43cf5eb72305a5e2e1136fb788574bf0ee61d19151f95b9916aa996f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764786177,
      "headline": "3 Potential Mid-Cap Biotech Buyout Targets In 2026",
      "id": 137674630,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190546601/image_2190546601.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Read about the 3 potential midcap biotech stocks primed for acquisition in 2026 amid rising M&A activity.",
      "url": "https://finnhub.io/api/news?id=b80d4fcf43cf5eb72305a5e2e1136fb788574bf0ee61d19151f95b9916aa996f"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
    "summary": "Merck & Co., Inc. (MRK) Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:00 PM ESTCompany ParticipantsEliav Barr - Chief Medical Officer...",
    "url": "https://finnhub.io/api/news?id=85c11bace6b0d9d6c4f04a65b68a4224c5ce835de528990ce1739228e8c536f7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764785004,
      "headline": "Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript",
      "id": 137674573,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. (MRK) Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:00 PM ESTCompany ParticipantsEliav Barr - Chief Medical Officer...",
      "url": "https://finnhub.io/api/news?id=85c11bace6b0d9d6c4f04a65b68a4224c5ce835de528990ce1739228e8c536f7"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK): Revisiting Valuation After a 22% One-Month Share Price Surge",
    "summary": "Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in the past 3 months, drawing fresh attention to its valuation. See our latest analysis for Merck. That surge comes after a more muted stretch, with the share price now at $101.03 and a modest year to date share price return. However, a solid five year total shareholder return suggests long term holders have still done well. If Merck’s move has you rethinking opportunities...",
    "url": "https://finnhub.io/api/news?id=592b16a3e1a4ada780f807165664ccedd0727a42e8b9a1c73559a72722f6cb51",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764774744,
      "headline": "Merck (MRK): Revisiting Valuation After a 22% One-Month Share Price Surge",
      "id": 137671078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) has quietly pulled ahead of many pharma peers, with the stock climbing about 22% over the past month and 20% in the past 3 months, drawing fresh attention to its valuation. See our latest analysis for Merck. That surge comes after a more muted stretch, with the share price now at $101.03 and a modest year to date share price return. However, a solid five year total shareholder return suggests long term holders have still done well. If Merck’s move has you rethinking opportunities...",
      "url": "https://finnhub.io/api/news?id=592b16a3e1a4ada780f807165664ccedd0727a42e8b9a1c73559a72722f6cb51"
    }
  },
  {
    "ts": null,
    "headline": "Buy Verizon, December's Ideal \"Safer\" Dog Of The Dow",
    "summary": "Read the latest Dogs of the Dow update: see which top dividend stocks offer optimal value, growth forecasts, and safe yields.",
    "url": "https://finnhub.io/api/news?id=2667faafae3ff28b914df962f1f36c6af7bda25b202492689598e8cf884cc067",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764763343,
      "headline": "Buy Verizon, December's Ideal \"Safer\" Dog Of The Dow",
      "id": 137672165,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219303612/image_1219303612.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Read the latest Dogs of the Dow update: see which top dividend stocks offer optimal value, growth forecasts, and safe yields.",
      "url": "https://finnhub.io/api/news?id=2667faafae3ff28b914df962f1f36c6af7bda25b202492689598e8cf884cc067"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript",
    "summary": "Merck & Co., Inc. (MRK) Evercore 8th Annual Healthcare Conference December 2, 2025 9:10 AM ESTCompany ParticipantsEliav Barr - Chief Medical Officer...",
    "url": "https://finnhub.io/api/news?id=7553d3dd1eed2cf7088901de42af2409b23016c637d78cf1478ce3dc4f8c507e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764735205,
      "headline": "Merck & Co., Inc. (MRK) Presents at Evercore 8th Annual Healthcare Conference Transcript",
      "id": 137669058,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Merck & Co., Inc. (MRK) Evercore 8th Annual Healthcare Conference December 2, 2025 9:10 AM ESTCompany ParticipantsEliav Barr - Chief Medical Officer...",
      "url": "https://finnhub.io/api/news?id=7553d3dd1eed2cf7088901de42af2409b23016c637d78cf1478ce3dc4f8c507e"
    }
  }
]